Stock Scorecard



Stock Summary for Harmony Biosciences Holdings Inc (HRMY) - $29.05 as of 2/27/2026 11:35:21 AM EST

Total Score

20 out of 30

Safety Score

55 out of 100

Currently on the following lists
Small Cap Stock List
Tim's Recommendation
Buy

Growth List Algorithm Criteria for HRMY

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for HRMY

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for HRMY

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for HRMY

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for HRMY (55 out of 100)

Stock Price Rating (Max of 10) 7
Historical Stock Price Rating (Max of 10) 9
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 5
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 5
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 9
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for HRMY

Truist Securities Downgrades Harmony Biosciences Holdings, Inc. (HRMY) to Hold After Patent Trial Developments 2/26/2026 1:52:00 PM
Harmony Biosciences (HRMY) Is Down 20.1% After Reaffirming WAKIX Outlook and Winning Pediatric Approval 2/26/2026 8:52:00 AM
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Average Recommendation of "Moderate Buy" by Analysts 2/26/2026 6:52:00 AM
Analysts Offer Insights on Healthcare Companies: ProQR (PRQR), Immunic (IMUX) and Harmony Biosciences Holdings (HRMY) 2/25/2026 3:53:00 PM
UBS cuts Harmony Biosciences stock price target on earlier Wakix generic entry 2/25/2026 1:53:00 PM
Harmony Biosciences Holdings, Inc. Experiences Revision in Its Stock Evaluation Amid Market Volatility 2/25/2026 1:53:00 PM
Harmony Biosciences Holdings Inc. (HRMY) PT Lowered to $36 at UBS 2/25/2026 12:53:00 PM
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q4 2025 Earnings Call Transcript 2/25/2026 8:19:00 AM
Harmony Biosciences Holdings, Inc. SEC 10-K Report 2/24/2026 1:52:00 PM
Narcolepsy drug WAKIX nears $1B blockbuster year for Harmony Biosciences 2/24/2026 12:52:00 PM

Financial Details for HRMY

Company Overview

Ticker HRMY
Company Name Harmony Biosciences Holdings Inc
Country USA
Description Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 9/30/2025
Next Earnings Date 3/3/2026

Stock Price History

Last Day Price 29.05
Price 4 Years Ago 55.10
Last Day Price Updated 2/27/2026 11:35:21 AM EST
Last Day Volume 1,374,462
Average Daily Volume 1,042,513
52-Week High 40.87
52-Week Low 25.52
Last Price to 52 Week Low 13.83%

Valuation Measures

Trailing PE 8.89
Industry PE 26.08
Sector PE 46.86
5-Year Average PE 21.38
Free Cash Flow Ratio 2.59
Industry Free Cash Flow Ratio 12.68
Sector Free Cash Flow Ratio 25.71
Current Ratio Most Recent Quarter 3.75
Total Cash Per Share 11.23
Book Value Per Share Most Recent Quarter 14.50
Price to Book Ratio 1.99
Industry Price to Book Ratio 50.08
Sector Price to Book Ratio 52.77
Price to Sales Ratio Twelve Trailing Months 1.97
Industry Price to Sales Ratio Twelve Trailing Months 38.92
Sector Price to Sales Ratio Twelve Trailing Months 22.39
Analyst Buy Ratings 7
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 57,596,000
Market Capitalization 1,673,163,800
Institutional Ownership 91.49%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 10.10%
Annual Earnings Growth 12.91%
Reported EPS 12 Trailing Months 3.17
Reported EPS Past Year 3.11
Reported EPS Prior Year 2.74
Net Income Twelve Trailing Months 185,676,000
Net Income Past Year 145,493,000
Net Income Prior Year 128,853,000
Quarterly Revenue Growth YOY 28.70%
5-Year Revenue Growth 160.18%
Operating Margin Twelve Trailing Months 27.40%

Balance Sheet

Total Cash Most Recent Quarter 646,999,000
Total Cash Past Year 453,001,000
Total Cash Prior Year 311,660,000
Net Cash Position Most Recent Quarter 498,493,000
Net Cash Position Past Year 289,985,000
Long Term Debt Past Year 163,016,000
Long Term Debt Prior Year 178,566,000
Total Debt Most Recent Quarter 148,506,000
Equity to Debt Ratio Past Year 0.80
Equity to Debt Ratio Most Recent Quarter 0.85
Total Stockholder Equity Past Year 659,155,000
Total Stockholder Equity Prior Year 466,992,000
Total Stockholder Equity Most Recent Quarter 835,123,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 296,894,000
Free Cash Flow Per Share Twelve Trailing Months 5.15
Free Cash Flow Past Year 218,668,000
Free Cash Flow Prior Year 219,075,000

Options

Put/Call Ratio 0.63
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.00
MACD Signal 0.00
20-Day Bollinger Lower Band 26.52
20-Day Bollinger Middle Band 34.65
20-Day Bollinger Upper Band 42.79
Beta 0.84
RSI 20.27
50-Day SMA 0.00
150-Day SMA 0.00
200-Day SMA 36.99

System

Modified 2/26/2026 12:39:59 AM EST